HIGH GRADE OVARIAN SEROUS ADENOCARCINOMA
Clinical trials for HIGH GRADE OVARIAN SEROUS ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HIGH GRADE OVARIAN SEROUS ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for HIGH GRADE OVARIAN SEROUS ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for Tough-to-Treat cancers
Disease control OngoingThis study tests two drug combinations (olaparib plus either vistusertib or capivasertib) in people with recurrent endometrial, triple-negative breast, ovarian, or related cancers. The goal is to find the safest dose and see if the drugs can control tumor growth. About 159 adults…
Matched conditions: HIGH GRADE OVARIAN SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 03:32 UTC
-
New drug combo shows promise for recurrent ovarian and endometrial cancers
Disease control OngoingThis early-phase study tests a combination of two oral and intravenous drugs (niraparib and copanlisib) in about 31 people whose endometrial, ovarian, or related cancers have returned. The main goal is to find the safest dose and understand side effects. Participants must have ce…
Matched conditions: HIGH GRADE OVARIAN SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 03:26 UTC
-
New drug shows promise in shrinking ovarian tumors before surgery
Disease control OngoingThis early-phase trial is testing the drug olaparib in 15 people with newly diagnosed BRCA-mutant ovarian, fallopian tube, or peritoneal cancer before they have surgery. The goal is to see if taking olaparib for two cycles can safely shrink tumors and stop them from growing. Olap…
Matched conditions: HIGH GRADE OVARIAN SEROUS ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:56 UTC